ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 2029년에는 연간 평균 성장률(CAGR) 16%로 성장할 전망이며, 62억 7,450만 달러로 성장이 예측됩니다. 예측 기간의 성장은 고령자 증가, 환자의 의식 고조, 신흥 시장 성장, 정부의 지원 시책, 표적 치료에 대한 수요 고조에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 피하주 제제로의 시장 시프트, 바이오시밀러와의 경합 격화, 시장 진입 기업 간의 전략적 제휴, 환자 중심의 치료 옵션으로의 주력, 신흥국 지역으로의 지리적 진출 등을 들 수 있습니다.
자가면역 질환의 유병률 증가는 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장의 성장을 가속할 것으로 예측됩니다. 자가면역 질환은 면역계가 실수로 체내 세포, 조직, 장기를 공격해 염증이나 잠재적인 손상을 일으키면서 발병합니다. 이러한 질환의 증가는 면역계에 영향을 미치는 유전적 소인, 환경 요인, 감염증, 라이프 스타일의 변화 등의 요인과 관련되어 있습니다. 리툭시맙은 건강한 조직을 잘못 공격하는 특정 면역세포(B세포)를 표적으로 고갈시킴으로써 자가면역 질환 관리에 도움이 됩니다. 예를 들면, 2023년 10월에 잉글랜드 국민 보건 서비스(National Health Service England)가 발표한 보고서에서는 당뇨병 유병률이 증가 일로를 걷고 있는 것이 강조되고 있습니다. 잉글랜드에서는 2021-2022년 1형 당뇨병 환자가 27만 935명으로 증가했습니다. 이러한 자가면역 질환의 이환율 상승은 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장을 견인하는 중요한 요인입니다.
헬스케어 지출 증가도 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장의 성장을 가속할 것으로 예상되는 요인의 하나입니다. 헬스케어 지출에는 개인적인 헬스케어, 예방 서비스, 건강 상태 개선을 목적으로 한 공중 보건 활동 등 헬스케어 상품과 서비스에 대한 모든 지출이 포함됩니다. 이 지출은 인구의 고령화, 만성질환 증가, 의료기술 진보, 약값의 급등, 의료 서비스에 대한 수요 증가 등의 요인으로 인해 증가하고 있습니다. 헬스케어 지출 증가는 리툭산 하이세라 및 리툭산 맙테라와 같은 선진 치료에 대한 접근성을 개선하고 종양학과 자가면역 질환 치료에 있어서 효과적인 치료법에 대한 수요를 끌어올립니다. 예를 들어 2024년 5월 국가통계국 보고서에 따르면 영국의 헬스케어 지출은 2022-2023년 5.6% 증가한 반면 2022년 증가율은 0.9%로 둔화했습니다. 장기적인 의료 사회 보장 지출도 2022년에는 실질 기준으로 2.8% 증가했습니다. 헬스케어 지출의 증가는 리툭산 하이세라 및 리툭산 맙테라 시장의 성장에 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여 경로(ROA)
작용기전(MOA)
안전성 및 유효성
제4장 시장 동향 및 전략
제5장 시장 : 금리, 인플레이션, 지정학적 요인, 신형 코로나와 그 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 성장률 분석
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 실적 : 규모 및 성장(2019-2024년)
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) : 전체 시장 규모(TAM)
제7장 세계의 가격 분석 및 예측
제8장 시장 세분화
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
10ml
50ml
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
피하
정맥내
비경구
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
온라인 약국
기타 유통 채널
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
비호지킨 림프종
만성 림프성 백혈병
류마티스 관절
기타
제9장 세계의 임상적응증 역학
약제의 부작용
임상적응증의 발병률 및 유병률
제10장 지역별 및 국가별 분석
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도 및 기업 프로파일
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 경쟁 구도
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장 : 기업 프로파일
F. Hoffmann-La Roche AG(Genentech Inc.)
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹 및 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 부문 및 전략
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장(2029년) : 새로운 기회를 제공하는 국가
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장(2029년) : 새로운 기회를 제공하는 부문
리툭산 하이세라 및 리툭산 맙테라(리툭시맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
AJY
영문 목차
영문목차
Rituxan Hycela and Rituxan MabThera (rituximab) are monoclonal antibody therapies that target CD20-positive B-cells. These treatments are used for conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan Hycela is a subcutaneous formulation, while Rituxan MabThera is administered intravenously.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main formulations of Rituxan Hycela and Rituxan MabThera (rituximab) are available in 10 ml and 50 ml vials. The 10 ml vial of Rituxan Hycela is intended for patients who require a smaller dose of the medication, often suitable for those beginning treatment or needing lower dosages, allowing for personalized care. The medication is administered through subcutaneous, intravenous, and parenteral routes and is distributed through hospital pharmacies, online pharmacies, and other channels. It is used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions.
The rituxan hycela, rituxan mabthera (rituximab) market research report is one of a series of new reports from The Business Research Company that provides rituxan hycela, rituxan mabthera (rituximab) market statistics, including the rituxan hycela, rituxan mabthera (rituximab) industry's global market size, regional shares, competitors with a rituxan hycela, rituxan mabthera (rituximab) market share, detailed rituxan hycela, rituxan mabthera (rituximab) market segments, market trends and opportunities, and any further data you may need to thrive in the rituxan hycela, rituxan mabthera (rituximab) industry. This rituxan hycela, rituxan mabthera (rituximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The rituxan hycela, rituxan mabthera (rituximab) market size is expected to see rapid growth in the next few years. It will grow to $6,274.5 million in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising geriatric population, increasing patient awareness, emerging market growth, supportive government policies, and growing demand for targeted therapies. Major trends in the forecast period include market shifts towards subcutaneous formulations, increased competition from biosimilars, strategic collaborations among market players, focus on patient-centric treatment options, and geographic expansion into developing regions.
The increasing prevalence of autoimmune diseases is expected to drive the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, leading to inflammation and potential damage. The rise in these conditions is linked to factors such as genetic predisposition, environmental factors, infections, and lifestyle changes that impact the immune system. Rituximab helps manage autoimmune diseases by targeting and depleting specific immune cells (B-cells) that mistakenly attack healthy tissues. For example, in October 2023, a report from the National Health Service England highlighted the ongoing rise in the prevalence of diabetes. In England, the number of people with type 1 diabetes increased to 270,935 between 2021 and 2022. This rising incidence of autoimmune diseases is a key factor driving the market for Rituxan Hycela and Rituxan MabThera (rituximab).
The growing healthcare expenditure is another factor expected to propel the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Healthcare expenditure encompasses all spending on healthcare goods and services, including personal health care, preventive services, and public health activities, which aim to improve health outcomes. This expenditure is increasing due to factors such as an aging population, the rise of chronic diseases, advancements in medical technology, high drug prices, and increased demand for healthcare services. Higher healthcare spending improves access to advanced treatments such as Rituxan Hycela and Rituxan MabThera, boosting demand for effective therapies in the treatment of oncology and autoimmune diseases. For instance, in May 2024, a report from the Office for National Statistics noted that healthcare expenditure in the UK rose by 5.6% from 2022 to 2023, compared to a slower growth rate of 0.9% in 2022. Long-term health and social care expenditure also saw an increase of 2.8% in real terms in 2022. The rise in healthcare spending is contributing to the growth of the Rituxan Hycela and Rituxan MabThera market.
A significant trend in the Rituxan Hycela and Rituxan MabThera (rituximab) market is the development of biosimilar anti-CD20 monoclonal antibodies, which offer cost-effective alternatives and improve patient access to treatment. Biosimilars are biologic drugs highly similar to reference products such as Rituxan, designed to target CD20 on B-cells and provide a more affordable treatment option. For example, in June 2022, Amgen received approval from the US Food and Drug Administration (FDA) for RIABNI (rituximab-arrx), a biosimilar to Rituxan, for use in combination with methotrexate in adults with moderate to severely active rheumatoid arthritis who have not responded well to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is a biosimilar version of Rituxan, containing the same amino acid sequence and available in the same dosage form, strength, and administration route. The development of such biosimilars is expected to further drive the market for Rituxan Hycela and Rituxan MabThera.
The key company operating in the rituxan hycela, rituxan mabthera (rituximab) market is F. Hoffmann-La Roche AG (Genentech Inc.)
North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2024. The regions covered in rituxan hycela and rituxan mabthera (rituximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rituxan hycela and rituxan mabthera (rituximab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rituxan hycela and rituxan mabthera (rituximab) market consists of sales of MabThera 1600 mg and ritunxan hycela (rituximab and hyaluronidase human injection). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rituxan Hycela, Rituxan Mabthera (Rituximab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rituxan hycela, rituxan mabthera (rituximab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rituxan hycela, rituxan mabthera (rituximab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rituxan hycela, rituxan mabthera (rituximab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: 10ml; 50ml
2) By Route Of Administration: Subcutaneous; Intravenous; Parenteral
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Others Distribution Channel
4) By Application: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis; Other Applications
Companies Mentioned: F. Hoffmann-La Roche AG (Genentech Inc.)
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
3. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends And Strategies
5. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Growth Analysis And Strategic Analysis Framework
6.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
8.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10ml
50ml
8.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Subcutaneous
Intravenous
Parenteral
8.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Hospital Pharmacy
Online Pharmacy
Others Distribution Channel
8.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Other Applications
9. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Regional And Country Analysis
10.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
10.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.3. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
11.4. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
12. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
12.1. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
12.2. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.3. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
12.4. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
13. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
13.1. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.2. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
13.3. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
14.1. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
14.2. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.3. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
14.4. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
15.1. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.2. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
15.3. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
16.1. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
16.2. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.3. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
16.4. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
17.1. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
17.2. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.3. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
17.4. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
18.1. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.2. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
18.3. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.1. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.2. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
19.3. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
20.1. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.2. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
20.3. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
21.1. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
21.2. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.3. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
21.4. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
22.1. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
22.2. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.3. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
22.4. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
23.1. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
23.2. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.3. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
23.4. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.2. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.3. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
24.4. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
25.1. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
25.2. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.3. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
25.4. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
26.1. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
26.2. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.3. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
26.4. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market
27.1. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
27.2. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.3. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
27.4. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
28. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Competitive Landscape And Company Profiles
